The global BCL B cell lymphoma inhibitors market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). BCL-2, also known as B Cell Lymphoma 2, is a protein-encoding gene belonging to the B cell lymphoma family. The market growth is majorly attributable to the growth in the prevalence of diffuse B cell lymphoma, a common type of non-Hodgkin lymphoma. For instance, according to an article by Lymphoma Research Foundation in 2019, in the US, DLBCL accounted for 22% of newly diagnosed B cell lymphoma cases. Around 18,000 people globally are diagnosed with DLBCL each year.
Adding to this, the disease affects people over 60 years of age. According to the American Cancer Society in 2019, an estimated 20,720 people were diagnosed with chronic lymphocytic lymphoma. Moreover, 90% of the people diagnosed with this form of lymphoma are estimated to affect people above 50 years of age. In the US, 2,220 men and 1,710 women are expected to be suffering from chronic lymphocytic lymphoma every year. Moreover, as per the American Cancer Society, about 3,930 mortalities were anticipated to take place in 2019.
To Request a Sample of our Report on Global BCL B Cell Lymphoma Inhibitors Market: https://www.omrglobal.com/request-sample/bcl-b-cell-lymphoma-inhibitors-market
Further, there are various inhibitor drugs being approved in the market that spur market growth. For instance, Venetoclax is the only and first approved FDA BCL-2 inhibitor drug for chronic lymphocytic lymphoma patients. Although various clinical trials are being carried out for the development of new BCL-2 inhibitors.
Some key players operating in the market include AbbVie, Roche, Abcam, Biorbyt, Biovison, and Tocris Bioscience. These players are eyeing on strengthening their position in the market by adopting various strategies as mergers and acquisitions, partnerships, collaborations, new product launch and development in the existing product portfolio, and so on.
Market Coverage
· The market number available for – 2020-2027
· Base year- 2020
· Forecast period- 2021-2027
· Segment Covered
· Regions Covered- Globally
· Competitive Landscape: AbbVie, Roche, Abcam, Biorbyt, Biovison, and Tocris Bioscience
(Get 15% Discount on Buying this Report)
A full Report of Global BCL B Cell Lymphoma Inhibitors Market is Available at: https://www.omrglobal.com/industry-reports/bcl-b-cell-lymphoma-inhibitors-market
Global BCL B Cell Lymphoma Inhibitors Market – Segmentation
By Therapy
• Monotherapy
• Combination Therapy
By Type
• Positive Lymphoma
• Follicular Lymphoma
Global BCL B Cell Lymphoma Inhibitors Market Segmentation by Region
North America
· United States
· Canada
Europe
· UK
· Germany
· Spain
· France
· Italy
· Rest of Europe
Asia-Pacific
· India
· China
· Japan
· South Korea
· Rest of APAC
Rest of the World
Reasons to buy from us –
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
(This release has been published on Global Market Post. Global Market Post is not responsible for any content included in this release.)
